Aerie Pharmaceuticals Inc (AERI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AERI quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Aerie Pharmaceuticals Inc adapts its cash strategy across cycles.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2021)
12 Months
(Dec 31 2020) (Dec 31 2019) (Dec 31 2018) (Dec 31 2017)
Operating Activities
Income-74.81
Depreciation & amortization6.40
Amortization of Other Assets31.10
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-12.10
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation29.52
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Loss, before Tax0.00
Amortization Of Debt Discount Premium One-
Induced Conversion Of Convertible Notes-
Increase Decrease In Operating Lease Liability-5.41
Increase Decreasein Operating Lease Liabilities-90.00
Increase Decrease In Licensing Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-12.81
Increase (Decrease) in Accounts Payable and Other Operating Liabilities21.58
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-7.29
Other Working Capital0.00
Other Noncash Income (Expense)1.19
Other net0.00
Payments for (Proceeds from) Other Operating Activities13.46
Discontinued operations0.00
Net Cash flow from Operating Activities-99.15
Investing Activities
Capital Expenditures-3.29
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt-132.36
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments117.45
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-18.20
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment For Initial Public Offering Cost-
Proceeds From Exercise Of Stock Purchase Rights-
Payments of Stock Issuance Costs Offering Expenses-
Proceeds Relatedto Issuance of Stock For Stock Based Compensation Arrangementsnet-
Proceeds Relatedto Issuance of Stock For Stock Based Compensation Arrangements Net2.97
Proceeds Payments Related To Issuance of Stock For Stock Based Compensation Arrangements-
Payments Of Call Options-
Payments Related To Issuance Of Stock For Stock Based Compensation Arrangements-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.97
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-102.45
Total Cash Flow-114.38
4 historic quarters locked

Sign in to unlock the full Aerie Pharmaceuticals Inc cash flow history.

About Aerie Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001337553-22-000041

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License